Products

Azithromycin Tablet GMP Manufacturer Medicine

China Azithromycin Tablet GMP Manufacturer Medicine, Find details about China Azithromycin, Tablet from Azithromycin Tablet GMP Manufacturer Medicine

Model NO.
250mg
Pharmaceutical Technology
Chemical Synthesis
Drug Reg./Approval No.
20045804
Production Line
GMP Approved
Trademark
SHIMEN
Transport Package
Carton
Specification
250mg
Origin
Hebei
HS Code
3004909099
Model NO.
250mg
Pharmaceutical Technology
Chemical Synthesis
Drug Reg./Approval No.
20045804
Production Line
GMP Approved
Trademark
SHIMEN
Transport Package
Carton
Specification
250mg
Origin
Hebei
HS Code
3004909099
Azithromycin Dispersable Tablet

Classification: Antibiotic, macrolide
Action/Kinetics: A macrolide antibiotic derived from erythromycin. The drug acts by binding to the P site of the 50S ribosomal subunit and may inhibit RNA-dependent protein synthesis by stimulating the dissociation of peptidyl t-RNA from ribosomes. Rapidly absorbed and distributed widely throughout the body. Food increases the absorption of azithromycin. Time to reach maximum concentration: 2.2 hr. t1/2, terminal: 68 hr. A loading dose will achieve steady-state levels more quickly. Mainly excreted unchanged through the bile with a small amount being excreted through the kidneys.

Shijiazhuang No. 4 Pharmaceutical Co., Ltd., as one of the leading manufacturers in Chinese pharmaceutical industry and a well-known brand, has a business history of seventy years. The company principally specializes in R & D, manufacture and sales of wide types of drugs mainly including intravenous infusion.
The production lines have achieved full automation control and information control in the production process and logistics process and reached international advanced level by integrating the world's leading equipment and technology.
With product quality as its life, the Company always organizes production in strict accordance with GMP requirements, establishes and implements superior service concepts and measures and provides guarantee for the health of the majority of patients at home and abroad with excellent quality products and services.
The Company has a powerful R&D team and made a number of achievements in scientific research and undertaken many major scientific and technological innovation projects and industrialization projects by firmly grasping the pulse of pharmaceutical development, increasing new product development investment and accelerating the pace of technological innovation.
Large volume injection is the key products, tablets, capsules, small volume injection and other forms are manufactured also. Recently API has been put into production and sales. There are more than ten international advanced production lines for the large volume injection, its production scale, technology level, brand influence and economic benefit are on the forefront of domestic counterparts, and it has become one of China's top 100 pharmaceutical industry enterprises and China's top 10 chemical and pharmaceutical industry preparation export-oriented excellent enterprise brands for many consecutive years.
The products are radiated to all provinces, autonomous regions and municipalities in China and also exported to many overseas markets, including more than 80 countries in Asia, Americas, Europe, Oceania, Africa and other continents, and it has become one of the main export enterprises of infusion products.


 

You Might Also Like